一颗急救药安宫牛黄丸，医院采购挂网价比药店贵超4倍，离谱差价背后的定价迷局

Core Viewpoint - The Jilin Provincial Public Resource Trading Center has initiated a price verification for 48 drugs with significant price discrepancies between retail and hospital channels, marking a significant step in addressing the issue of higher hospital drug prices compared to retail prices [1][8]. Group 1: Price Discrepancies - The price differences for the 48 drugs range from 1.3 times to 5.2 times, with notable examples including the inhaled budesonide suspension showing a price difference of 5.2 times and the An Gong Niu Huang Wan produced by Shandong Hongjitang and Beijing Tongrentang exceeding 4 times [1][6]. - The inhaled budesonide suspension has a procurement price of 388.11 yuan per mg in medical institutions, while the retail price is only 75 yuan, highlighting a significant burden on patients and waste of medical insurance funds [2][6]. - The An Gong Niu Huang Wan from Shandong Hongjitang has a procurement price of 434.9 yuan, while the retail price is 99 yuan, resulting in a price difference of 4.4 times [6][5]. Group 2: Market Dynamics - The rapid development of retail pharmacies and online drug purchasing platforms has intensified price competition, yet some drugs remain at high procurement prices in medical institutions, leading to widening price gaps [1][7]. - The price verification process is based on the "mode price," which reflects the most frequently occurring price after excluding outliers, ensuring a more accurate representation of market prices [7][10]. - The price discrepancies are attributed to various factors, including the lengthy procurement process in medical institutions and different pricing strategies adopted by pharmaceutical companies for retail and institutional sales [7][10]. Group 3: Regulatory Implications - The price verification initiative in Jilin is part of a broader national effort by the National Medical Insurance Administration to address drug pricing issues, indicating a shift towards comprehensive price management across all channels [1][8]. - Pharmaceutical companies are required to adjust their listed prices to not exceed 1.3 times the retail mode price by February 2, 2026, or face penalties such as suspension of online trading qualifications [10][11]. - Similar regulatory measures are being explored in other provinces, suggesting a trend towards stricter monitoring and management of drug pricing across the country [11].